RESEARCH STATUSFor research use only. Not for human consumption. Retatrutide is investigational and not FDA-approved.

READ THE EVIDENCE, NOT THE HYPE.

SCIENCE
LIBRARY.

We separate human clinical evidence from animal, cellular, and mechanistic research so you can see what is known, what is promising, and what remains unanswered.

Human trialHuman clinical data

Controlled or observational research involving people.

PreclinicalPreclinical data

Animal or cell research—not proof of a human outcome.

MechanisticMechanistic rationale

Explains a biological pathway, not a demonstrated benefit.

RETA / 001

TRIPLE-RECEPTOR
RESEARCH

Retatrutide is a single investigational molecule designed to activate three nutrient-responsive hormone receptors: GIP, GLP-1, and glucagon.

Explore RETA science →
01 / GIP

Glucose-dependent insulinotropic polypeptide

Studied for its role in nutrient signaling and glucose-dependent insulin response.

02 / GLP-1

Glucagon-like peptide-1

Studied in appetite signaling, gastric emptying, and glucose-dependent insulin secretion.

03 / GCG

Glucagon receptor

Studied for roles in hepatic energy metabolism and energy expenditure.

GLOW / 002

THREE RESEARCH
PATHWAYS

GLOW combines GHK-Cu, BPC-157, and TB-500. The combined blend itself has not been established in human clinical trials.

Explore GLOW science →
Preclinical

GHK-Cu

Studied in cellular signaling, collagen-related pathways, inflammation, and tissue repair models.

Preclinical

BPC-157

Most published findings are animal studies. Reviews find major gaps in human safety, dosing, and efficacy data.

Preclinical

TB-500 / Thymosin β4 research

Thymosin β4 has been studied in cell and animal models of migration, angiogenesis, and wound repair. TB-500 products are not established human therapies.

PRIMARY SOURCES OPEN THE ORIGINAL RESEARCH

GO DEEPER.